Benzoyl Peroxide for Acne: How It Works

Skincare Science  ·  Acne Actives

Benzoyl Peroxide for Acne: How It Works and Who It Suits

// The short answer

Benzoyl peroxide kills acne-causing bacteria by flooding them with free-radical oxygen species they cannot adapt to. It is one of the best-evidenced topical acne treatments available, with a strong recommendation in the 2024 AAD guidelines.22 Start at 2.5%: clinical trials show it works as well as higher concentrations with meaningfully less irritation.1

Benzoyl peroxide has been in dermatology for over 50 years, and the evidence base behind it is unusually solid. A Cochrane meta-analysis covering 120 randomized trials and nearly 30,000 participants confirms it outperforms placebo for acne.2 There are real tradeoffs: it dries skin, it bleaches fabric and hair, and new questions about benzene degradation deserve an honest answer. This guide covers all of it, without steering you toward or away from any brand.

Habib A MuflihFounder of MAXXING | Last updated: June 2026 | 12 min read Cosmetic skincare guide only. Supports-language throughout - not medical advice, diagnosis, or treatment. Consult a dermatologist for persistent or severe acne.
120
Randomized controlled trials in Cochrane BPO meta-analysis
Sutcliffe et al. 2020
52%
Inflammatory lesion reduction vs 34.7% for vehicle in 12-trial systematic review
Eichenfield et al. 2015
~80%
Lesion reduction by week 52 in Japanese long-term safety trial
Kawashima et al. 2017
0
Documented cases of bacterial resistance to benzoyl peroxide
StatPearls 2023
// What's in this guide
  1. How BPO works: the free-radical mechanism
  2. The clinical evidence
  3. Choosing a concentration: 2.5% vs 5% vs 10%
  4. Irritation and skin barrier damage
  5. Fabric and hair bleaching: what actually happens
  6. The benzene degradation question
  7. Which acne type is BPO actually right for?
  8. Topical acne actives compared
  9. How to use benzoyl peroxide
  10. Oil control alongside BPO: where niacinamide fits
  11. FAQ

01How BPO works: the free-radical mechanism

Benzoyl peroxide is an organic peroxide. When applied to skin, it rapidly degrades into benzoic acid and releases free-radical oxygen species. Those radicals oxidize and structurally destroy bacterial proteins, which kills Cutibacterium acnes (formerly Propionibacterium acnes) and other acne-associated bacteria within seconds to minutes at 5% concentration.8

The mechanism is non-specific. BPO does not lock onto a particular bacterial receptor or metabolic pathway, which is precisely why resistance cannot develop. There is no single target for bacteria to mutate around. After more than five decades of clinical use, no bacterial resistance to benzoyl peroxide has been documented.6

Beyond antibacterial activity, BPO also has comedolytic and mild anti-inflammatory properties. It accelerates the desquamation of follicular epithelium, which helps clear the clogged pores that precede inflammatory breakouts. This dual action is why guidelines position it as effective for both inflammatory papules and pustules as well as the non-inflamed microcomedones that turn into them.30

// Key takeaway

BPO kills bacteria by oxidative destruction, a mechanism that bypasses resistance entirely. No other topical antibacterial has this property, which is why dermatology guidelines recommend pairing any topical or oral antibiotic with BPO to protect against resistance development.22

How fast does it kill bacteria?

Contact time matters, and higher concentrations act faster in vitro. A 2022 study testing clinically isolated strains found:9

  • 1.25% BPO required 60 minutes of contact for bactericidal effect
  • 2.5% BPO required 15 minutes
  • 5% and 10% BPO required only 30 seconds

In practical leave-on use, even the slower-acting 2.5% formulation has extended contact with skin, which is why clinical outcomes at 2.5% and 5% are nearly identical despite the speed difference in vitro.

02The clinical evidence

The evidence base for benzoyl peroxide is one of the strongest in topical dermatology. The 2020 Cochrane systematic review analyzed 120 randomized controlled trials with 29,592 participants and confirmed BPO outperforms placebo for participant-reported acne improvement (risk ratio 1.27 over 10 to 12 weeks).2 The same review found little meaningful difference between BPO alone and adapalene, or BPO and clindamycin, in participant-assessed outcomes.

A complementary 2015 systematic review of 12 vehicle-controlled trials (4,822 patients) found BPO reduced total lesion counts by 44.3% versus 27.8% for vehicle. Inflammatory lesion reduction was 52.1% versus 34.7%.3 The authors noted a substantial placebo response in acne trials generally, suggesting the actual treatment effect may be even larger than comparisons against vehicle show.

Long-term data is also available. A 52-week open-label trial in 458 Japanese patients using 2.5% and 5% gels once daily found lesion counts declined approximately 65% by week 12, reaching around 80% by week 52. Adverse events dropped sharply after the first three months, and no bacterial resistance developed.4

// Key takeaway

BPO has Grade A evidence for inflammatory lesion reduction - the strongest category in the 2004 Lancet meta-analysis, where salicylic acid received Grade B and insufficient data limited conclusions on nicotinamide and zinc.21

Combinations perform better than monotherapy

A consistent finding across trials is that BPO in fixed combination with a retinoid or antibiotic outperforms BPO alone. A 2009 review of clindamycin 1.2% plus BPO 2.5% across 2,813 patients showed 64.1% inflammatory lesion reduction versus 54.0% for clindamycin alone.11 A 2018 randomized six-month trial found that adapalene 0.3% combined with BPO 2.5% not only cleared existing lesions but significantly reduced new atrophic acne scar formation - by approximately four scars per half-face relative to vehicle at 24 weeks.15

03Choosing a concentration: 2.5% vs 5% vs 10%

The landmark comparison study on this question was published in 1986 and remains the most cited reference. Three double-blind trials in 153 patients compared 2.5%, 5%, and 10% formulations head-to-head on inflammatory lesions. The result: all three concentrations performed equivalently on lesion reduction. But 2.5% produced significantly less desquamation, erythema, and burning sensation compared to 10%, while performing similarly to 5%.1

StatPearls, the NCBI's clinical pharmacology reference, recommends initiating BPO treatment with lower-strength preparations for exactly this reason.26 The practical guidance from dermatologists aligns: start at 2.5%, tolerate for two to four weeks, then escalate if needed.

Higher concentrations have one clear advantage: speed of bacterial kill. At 5% and above, BPO requires only 30 seconds of contact to achieve a bactericidal effect against clinical isolates, making them suitable for rinse-off wash formulations where leave-on contact time is limited.9 For leave-on gels and creams, the contact time difference is largely irrelevant.

04Irritation and skin barrier damage

Irritation is the most common reason people stop using benzoyl peroxide. A survey of 200 people using a BPO-combination product for at least five days per week over six months found dry skin in 55%, flaky or peeling skin in 45%, irritated skin in 44%, itchy skin in 39%, and redness in 37%.28 Most adapted by reducing frequency or applying only to active breakout areas. About 41% added a moisturizer.

There is now measurable skin barrier data behind that experience. A 2022 study examining adapalene combined with BPO found elevated transepidermal water loss (TEWL) in treated groups compared to untreated skin, with correlated clinical signs of erythema, dryness, and desquamation.29 BPO is genuinely disrupting barrier function, not just causing temporary surface dryness.

The good news is that this is manageable. A double-blind RCT published in 2023 tested ceramide-containing moisturizers as adjuncts to adapalene 0.3% / BPO 2.5% treatment. The ceramide group showed significantly lower TEWL at all timepoints, statistically lower dryness scores throughout the 12-week trial, and interestingly, also reduced inflammatory lesion counts compared to the non-ceramide group.30b A barrier-supporting moisturizer is not optional when using BPO; it is part of the regimen.

// Key takeaway

BPO genuinely damages the skin barrier during use. Pairing it with a ceramide-containing moisturizer (like MAXXING Damage Control) reduces both irritation and, in one RCT, acne lesion counts. This is not just comfort management - it may improve outcomes.

The FDA adverse event database (FAERS) analysis covering 2004 to 2024 found skin and subcutaneous tissue disorders represented the largest category of BPO reports. High-signal adverse events included chemical burns (reporting odds ratio 174.52), application site swelling (ROR 124.52), and facial swelling (ROR 83.59), with nearly half of reported events occurring within the first day of use.27 These are mostly acute reactions in users who applied too much too soon, reinforcing the case for low-and-slow introduction.

05Fabric and hair bleaching: what actually happens

This is not a minor inconvenience - it is a real-world problem that causes expensive damage. Benzoyl peroxide is a strong oxidizing agent. It reacts with the dye molecules in textiles and breaks the chemical bonds that give fabric its color. The effect is usually permanent and often dramatic on dark fabrics.32

Hair bleaches even faster than fabric. The keratinized fiber structure of hair - essentially the same protein composition as wool - reacts more rapidly to oxidizing agents than living skin cells. Eyebrows and the hairline near BPO application zones are the most frequent sites of incidental bleaching.31

Practical prevention:

  • Allow BPO to fully absorb (at least 2 to 3 minutes) before any fabric contact
  • Use white or old pillowcases and towels designated for BPO use
  • Apply away from the hairline when possible, or apply to skin before hair styling
  • Rinse immediately with cold water if BPO contacts a valued fabric

Light-colored fabrics can develop uneven fading even when damage is not immediately visible. The oxidative reaction continues at the dye-site level even after the product feels absorbed. Products marketed as "fabric-friendly" have reduced BPO contact residue but do not eliminate the chemistry.

06The benzene degradation question

In 2024, independent laboratory testing found that benzoyl peroxide can degrade into benzene, a known human carcinogen, under conditions of elevated temperature. Testing of 175 products found that some formed over 800 times the FDA's conditional limit of 2 parts per million when stored at elevated temperatures for days to weeks.23 The FDA conducted its own independent testing of 95 acne products in response.

The FDA's findings were more reassuring: more than 90% of tested products had either undetectable or extremely low benzene levels. Six products showed elevated levels and were voluntarily recalled.24

Whether this translates to cancer risk in users is a separate question - and the existing clinical data is reassuring on that point. A 2024 JAAD retrospective cohort study reviewed more than 260 million electronic medical records and found no association between benzoyl peroxide use and benzene-related cancers, including no increase in acute myeloid leukemia among BPO users.25 A 2025 Frontiers in Pediatrics review also found no detectable blood benzene elevation in BPO users and no increased hematologic malignancy risk in matched control studies.25b

// Key takeaway

The benzene degradation risk is real but temperature-dependent. Storage at room temperature away from heat sources appears to keep benzene formation within safe limits. Do not store BPO products in hot cars, near radiators, or in direct sunlight.

07Which acne type is BPO actually right for?

Benzoyl peroxide is primarily indicated for inflammatory acne: the red, tender papules and pustules caused by bacterial proliferation within the follicle. This is where its antibacterial mechanism delivers the most direct benefit, and it is where the strongest clinical trial evidence sits.

It also has comedolytic activity, making it useful for non-inflamed comedonal acne (blackheads and whiteheads), though retinoids are generally more potent in that role. For mixed acne, combinations of BPO with a retinoid address both pathways simultaneously.

BPO is generally less suitable for:

  • Rosacea: oxidative stress can worsen the inflammatory cascade in rosacea; microencapsulated BPO formulations specifically designed for rosacea (such as the FDA-approved Epsolay) exist for this, but standard OTC BPO should be avoided and a dermatologist consulted33
  • Very sensitive or eczema-prone skin: barrier disruption risk is high; ceramide moisturizers help but may not fully compensate
  • Purely hormonal, cystic acne: deep cystic nodules rarely respond to topical antibacterials alone and warrant medical evaluation

08Topical acne actives: an honest comparison

No single active treats all acne types equally well. The table below summarizes the main topical options by mechanism, best-suited acne type, and key tradeoffs, without recommending any specific products.

// Informational reference - acne types and topical active approaches
Active Primary mechanism Best-suited acne type Key tradeoffs Evidence level
Benzoyl peroxide Bactericidal via oxidative free radicals; also comedolytic Inflammatory (papules, pustules); mixed inflammatory + comedonal Skin dryness and barrier disruption; bleaches fabric and hair; benzene risk with heat storage Grade A (AAD 2024 first-line)22
Salicylic acid Beta-hydroxy acid; oil-soluble, dissolves in pores; keratolytic Comedonal (blackheads, whiteheads); oily, congested skin Weaker on inflammatory lesions than BPO; overuse can cause excessive peeling Grade B; less inflammatory lesion reduction than BPO in head-to-head comparisons21
Topical retinoids (adapalene, tretinoin) Accelerates cell turnover; normalizes follicular keratinization; anti-inflammatory Comedonal and mild to moderate inflammatory; post-acne texture; scar prevention Purging phase; photosensitivity; initial dryness and flaking; takes 8 to 12 weeks Strong; adapalene/BPO combination reduces new scar formation vs vehicle15
Azelaic acid Reduces bacterial proliferation; mild keratolytic; inhibits abnormal melanocyte activity Mild to moderate inflammatory; post-inflammatory hyperpigmentation; sensitive skin Slower onset; more application site reactions in one trial than BPO+clindamycin20; requires twice-daily use at 20% Probably worse treatment response than BPO in Cochrane acne review19
Niacinamide (topical) Sebum regulation; anti-inflammatory; supports skin barrier Oily skin; congestion control; complement to actives; post-acne redness Not a primary acne treatment; insufficient head-to-head trial data for lesion counts Limited primary acne evidence; supports barrier during active treatment19
Topical clindamycin / antibiotics Bacteriostatic; disrupts bacterial protein synthesis Inflammatory acne; moderate severity; typically combined with BPO or retinoid Resistance develops with monotherapy; should always be combined with BPO22 Comparable to BPO monotherapy alone but resistance is a significant clinical concern7
No brand names included. Evidence levels reference peer-reviewed published data. See References section for full citations.

09How to use benzoyl peroxide

The biggest predictor of tolerability is how the product is introduced. Most irritation issues come from applying too much too soon, not from BPO itself being inherently incompatible with a person's skin.

A practical introduction protocol

  • Week 1 to 2: Apply 2.5% BPO every other evening, to clean dry skin, to affected areas only. Use a thin layer - more product does not mean better results.
  • Week 3 to 4: If skin is tolerating this well, advance to daily evening use.
  • Week 4 onward: Assess lesion reduction. If inflammatory lesions are clearing, continue at 2.5%. If response is slow and tolerability is good, consider 5%.

Always follow with a ceramide moisturizer to support the skin barrier. MAXXING's Damage Control ceramide moisturizer is designed specifically to restore barrier function during active treatment routines. Applying it after BPO absorption is a straightforward way to offset the barrier disruption documented in clinical studies.

BPO does not require SPF by itself - it is not photosensitizing. However, if using BPO in combination with a retinoid (which does cause photosensitivity), morning SPF is essential.

What not to combine

BPO can oxidize and degrade certain other actives when applied in the same layer at the same time. Vitamin C (L-ascorbic acid) and BPO applied simultaneously can deactivate each other. Separate them to different times of day, or skip vitamin C on BPO application days if stacking is unavoidable. See the guide on building a layered acne routine for a more complete layering framework.

10Oil control alongside BPO: where niacinamide fits

Benzoyl peroxide targets the bacterial component of inflammatory acne. It does not directly address excess sebum production, which remains an underlying driver of both bacterial proliferation and pore congestion. For people dealing with visible shine and enlarged pores alongside breakouts, a niacinamide-based step can complement BPO by working on that parallel pathway.

Niacinamide supports sebum regulation through its role in keratinocyte differentiation and its known anti-inflammatory activity, and it reinforces the skin barrier that BPO disrupts. It is not a treatment for acne in the clinical trial sense - the science on niacinamide for oily skin covers what it realistically does and does not do. But as a supportive step alongside an antibacterial active, it has a logical role.

MAXXING's Clear Dominance serum combines niacinamide with zinc for oil and pore support. To be clear: it is not a benzoyl peroxide product, not a clinical acne treatment, and does not replace BPO for inflammatory acne. What it supports is the sebum and barrier side of the picture for people who want to address those as part of a broader routine. Apply it as a serum step before moisturizer, on mornings or evenings when BPO is not in the layer beneath it.

// Key takeaway

A sensible acne-focused routine for oily, breakout-prone skin might include: a gentle cleanser (like Fresh Start), BPO on affected areas as the active treatment step, a ceramide moisturizer to protect the barrier, and a niacinamide serum for oil and pore support on the days and layers where they do not conflict. That is not a product bundle pitch - it is just the logic of how these mechanisms work together.

For anything more complex - persistent severe acne, cystic nodules, acne with significant scarring, or acne that has not responded to OTC approaches after 12 weeks - a dermatologist visit is the right call, not another product swap. Also see the overview guide on salicylic acid for acne-prone skin if comedonal congestion is the main concern rather than active inflammatory lesions.

11FAQ

Yes - it has some of the strongest evidence of any topical acne ingredient. A Cochrane meta-analysis of 120 randomized trials (29,592 participants) confirmed it outperforms placebo for participant-assessed improvement.2 A 12-trial systematic review found 52.1% inflammatory lesion reduction versus 34.7% for vehicle.3 The 2024 AAD guidelines give it a strong recommendation as a first-line agent.22 Its main advantage over antibiotics is that bacteria cannot develop resistance to it.

Start at 2.5%. A 1986 three-arm double-blind study in 153 patients found 2.5% performed equally to 5% and 10% on inflammatory lesions while producing significantly less dryness, redness, and burning than the 10% preparation.1 Higher concentrations are faster-acting against bacteria in vitro but offer no additional clinical benefit in leave-on formulations when compared at standard application frequency.

BPO is a strong oxidizing agent that reacts with dye molecules in fabric, permanently breaking their color bonds. Dark fabrics show the most visible damage but lighter fabrics can develop uneven fading too. Hair bleaches even faster because the keratin fiber structure reacts more readily to oxidants than skin cells - eyebrows and hairlines are especially at risk.31 Allow BPO to fully absorb before fabric contact, use white designated towels and pillowcases, and rinse any accidental fabric contact immediately with cold water.

Long-term safety data is reassuring. A 52-week clinical trial found adverse events peaked in the first month and declined sharply thereafter, with no bacterial resistance development.4 A 1994 integrated carcinogenicity assessment found no association with skin cancer over 30+ years of clinical use at that point.34 A 2024 JAAD cohort study of over 260 million medical records found no association with benzene-related cancers including acute myeloid leukemia.25 The main practical long-term risk is skin barrier disruption, which ceramide-based moisturizers can meaningfully offset.30b

No. BPO kills bacteria through non-specific oxidative destruction - a mechanism bacteria cannot adapt to by mutation. No resistance has been documented after more than 50 years of clinical use.6 In contrast, clindamycin monotherapy consistently generates resistance. The 2024 AAD guidelines specifically mandate concurrent BPO use with any topical or oral antibiotic regimen to prevent resistance from developing.22

Independent testing in 2024 found BPO can degrade into benzene (a known carcinogen) under elevated-temperature conditions.23 The FDA's own testing found more than 90% of products had undetectable or very low benzene levels; six products with elevated levels were voluntarily recalled.24 A JAAD cohort study found no increased cancer risk in BPO users,25 and a 2025 review found no detectable blood benzene elevation in users.25b Store BPO at room temperature, away from heat and direct sunlight.

They target different aspects of acne. BPO is antibacterial and stronger on inflammatory lesions (papules, pustules). Salicylic acid is oil-soluble, penetrates pores, and is better suited to comedonal (blackhead and whitehead) acne. A 2003 double-blind comparison found BPO superior on inflammatory lesions; a 2004 meta-analysis found BPO plus salicylic acid in combination outperformed either alone on both inflammatory and non-inflammatory counts.21 If inflammatory acne is the primary concern, BPO is the stronger choice. For congested but non-inflamed skin, start with salicylic acid. See the guide on salicylic acid for acne-prone skin for more detail.

Yes, once tolerance is established. Start every other day for the first two weeks, then advance to daily use. The majority of tolerability issues in surveys come from overuse at the start - too much product, too often, before the skin adapts.28 Pairing BPO with a ceramide moisturizer has been shown in an RCT to significantly reduce dryness severity and barrier damage.30b If skin is still reactive at 2.5% every other day after four weeks, a conversation with a dermatologist is a reasonable next step.

Most people see a meaningful reduction in inflammatory lesions within 4 to 8 weeks. A 52-week clinical trial found roughly 65% lesion reduction by week 12, reaching around 80% by week 52 with continued daily use. If you are seeing no improvement after 12 weeks of consistent OTC use, a dermatologist visit is the right next step rather than switching products again.

Yes, leave-on formulations (gels, creams) are designed to stay on the skin. Applying a thin layer in the evening and leaving it overnight is the standard protocol. That extended contact time is actually why 2.5% leave-on formulations perform as well as higher concentrations clinically. Be aware that overnight wear increases fabric contact risk: use white or old pillowcases, as BPO will bleach fabric that it touches.

Habib A Muflih
Founder of MAXXING

Habib started MAXXING to build skincare products he actually wanted to use: formulated honestly, evidence-backed, and straightforward about what they do and do not do. He writes the brand's educational content with the same brief. If it is not supported by published clinical data, it does not make it into a MAXXING guide.

Last updated: June 2026  |  All citations link to peer-reviewed sources

Related reading

References

  1. Chalker DK, et al. "Comparing 2.5%, 5%, and 10% Benzoyl Peroxide on Inflammatory Acne Vulgaris." International Journal of Dermatology. 1986. doi:10.1111/j.1365-4362.1986.tb04534.x
  2. Sutcliffe G, et al. "Topical Benzoyl Peroxide for Acne (Cochrane Systematic Review)." Cochrane Database of Systematic Reviews. 2020. doi:10.1002/14651858.CD011154.pub2
  3. Eichenfield LF, et al. "Evaluating Clinical Trial Design: Systematic Review of Randomized Vehicle-Controlled Trials for BPO Topical Therapy for Acne." Archives of Dermatological Research. 2015. doi:10.1007/s00403-015-1568-1
  4. Kawashima M, et al. "Open-Label, Randomized, Multicenter Phase III Study: Safety and Efficacy of BPO Gel in Long-Term Use (52 Weeks)." The Journal of Dermatology. 2017. doi:10.1111/1346-8138.13630
  5. Kawashima M, et al. "Clinical Efficacy and Safety of Benzoyl Peroxide for Acne Vulgaris: Comparison Between Japanese and Western Patients." The Journal of Dermatology. 2017. doi:10.1111/1346-8138.13996
  6. Leyden JJ, et al. "A Current Review of Topical Benzoyl Peroxide: New Perspectives on Formulation and Utilization." Dermatology Clinics. 2009. doi:10.1016/j.det.2008.07.006
  7. Eady EA, et al. "The Role of Benzoyl Peroxide in the New Treatment Paradigm for Acne." Journal of Drugs in Dermatology. 2013.
  8. Melo P, et al. "Broad Spectrum In Vitro Microbicidal Activity of Benzoyl Peroxide Against Microorganisms Related to Cutaneous Diseases." The Journal of Dermatology. 2021. doi:10.1111/1346-8138.15739
  9. Decker A, et al. "Minimum Contact Time of 1.25%, 2.5%, 5%, and 10% Benzoyl Peroxide for a Bactericidal Effect Against Cutibacterium acnes." Clinical, Cosmetic and Investigational Dermatology. 2022. doi:10.2147/CCID.S359055
  10. Lookingbill DP, et al. "A Combination Benzoyl Peroxide and Clindamycin Topical Gel Compared with Benzoyl Peroxide, Clindamycin Phosphate, and Vehicle in Acne Vulgaris." Cutis. 2001.
  11. Leyden JJ, et al. "A New, Once-Daily, Optimized Fixed Combination of Clindamycin Phosphate 1.2% and Low-Concentration Benzoyl Peroxide 2.5% Gel for Moderate-to-Severe Acne." The Journal of Clinical and Aesthetic Dermatology. 2009.
  12. Cook-Bolden F, et al. "Sub-Group Analyses from a Trial of Fixed Combination Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Gel for Moderate-to-Severe Acne Vulgaris." Journal of Drugs in Dermatology. 2016.
  13. Amin MM, et al. "Comparative Efficacy of Clindamycin Phosphate with Benzoyl Peroxide versus Clindamycin Phosphate with Adapalene in Acne Vulgaris: A Systematic Review and Meta-Analysis." Scientific Reports. 2025. doi:10.1038/s41598-025
  14. Zahran A, et al. "Safety and Efficacy of Fixed-Dose Combination of Adapalene and Benzoyl Peroxide in Acne Vulgaris Treatment: A Systematic Review of Clinical Trials." Cureus. 2024. doi:10.7759/cureus.69614
  15. Dreno B, et al. "Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% in Moderate or Severe Facial Acne." Journal of the European Academy of Dermatology and Venereology. 2018. doi:10.1111/jdv.14782
  16. Tan J, et al. "Long-Term Effectiveness and Safety of Up to 48 Weeks' Treatment with Topical Adapalene 0.3%/BPO 2.5%." American Journal of Clinical Dermatology. 2019. doi:10.1007/s40257-019-00456-6
  17. Thiboutot DM, et al. "A 6-Month Maintenance Therapy with Adapalene-Benzoyl Peroxide Gel Prevents Relapse and Continuously Improves Efficacy Among Severe Acne Vulgaris Patients." British Journal of Dermatology. 2011. doi:10.1111/j.1365-2133.2011.10273.x
  18. Purdy S, et al. "Topical Azelaic Acid, Salicylic Acid, Nicotinamide, Sulphur, Zinc and Alpha-Hydroxy Acids for Acne (Cochrane Review)." Cochrane Database of Systematic Reviews. 2020. doi:10.1002/14651858.CD011368.pub2
  19. Purdy S, et al. "Topical Azelaic Acid, Salicylic Acid, Nicotinamide, Sulphur, Zinc and Alpha-Hydroxy Acids for Acne (Cochrane Review)." Cochrane Database of Systematic Reviews. 2020. doi:10.1002/14651858.CD011368.pub2
  20. Dreno B, et al. "A Multicentre Randomized Study Comparing Efficacy and Tolerability of Benzoyl Peroxide 3%/Clindamycin 1% with Azelaic Acid 20% in Mild-to-Moderate Acne Vulgaris." Journal of the European Academy of Dermatology and Venereology. 2016. doi:10.1111/jdv.13574
  21. Simonart T, et al. "Meta-Analysis Comparing Efficacy of Benzoyl Peroxide, Clindamycin, BPO with Salicylic Acid, and BPO/Clindamycin Combination in Acne." Lancet. 2004. doi:10.1016/S0140-6736(04)16660-X
  22. Zaenglein AL, et al. "Guidelines of Care for the Management of Acne Vulgaris (2024 AAD Update)." Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2023.12.017
  23. Valisure. "Valisure FDA Citizen Petition: Benzene in Benzoyl Peroxide Products (Laboratory Testing Report)." Valisure Newsroom. 2024.
  24. FDA. "FDA Independent Testing of Benzoyl Peroxide Acne Products for Benzene and Voluntary Recalls." FDA Drug Safety Communication. 2024.
  25. Mardones F, et al. "Benzoyl Peroxide for Acne Treatment Is Not Associated with an Increased Risk of Malignancy: A Retrospective Cohort Study." Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2024.07.004
  26. Vyas A, et al. "Benzoyl Peroxide in the Treatment of Acne: Are There Potential Health Concerns?" Frontiers in Pediatrics. 2025. doi:10.3389/fped.2025.1599491
  27. Kraft J, et al. "Benzoyl Peroxide." StatPearls Publishing / NCBI Bookshelf. 2023.
  28. Chen Z, et al. "A Comprehensive Study on Adverse Reactions of Benzoyl Peroxide in Dermatological Aesthetics Utilizing the FAERS Database." Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16793
  29. Tan J, et al. "How Patients Experience and Manage Dryness and Irritation from Acne Treatment." Journal of Drugs in Dermatology. 2011.
  30. Bettoli V, et al. "Effect of Topical Benzoyl Peroxide on Skin Barrier Integrity Assessed by Transepidermal Water Loss." International Journal of Medical Science and Clinical Research Studies. 2022.
  31. Tanghetti EA, et al. "Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment." Journal of Drugs in Dermatology. 2023. doi:10.36849/JDD.7097
  32. Draelos ZD. "New Perspectives on Benzoyl Peroxide Use in Inflammatory and Comedonal Acne Treatment." SKIN Therapy Letter. 2009.
  33. Stoner J. "Letter: Bleaching of Hair After Use of Benzoyl Peroxide Acne Lotions." Archives of Dermatology. 1974. doi:10.1001/archderm.1974.01630110047016
  34. Multiple authors. "BPO Fabric and Hair Bleaching: Practical User Warning (Synthesis of Evidence)." Consumer Education / Dermatology Practice Literature. 2024.
  35. Lehmann P, et al. "Epsolay (Microencapsulated Benzoyl Peroxide 5%) Cream for Topical Treatment of Rosacea." Skinmed. 2023.
  36. De Leo VA, et al. "Benzoyl Peroxide: An Integrated Human Safety Assessment for Carcinogenicity." Dermatology. 1994. doi:10.1159/000246724
  37. Swinyer LJ, et al. "Comparison of a Salicylic Acid Cleanser and a Benzoyl Peroxide Cleanser for Acne Vulgaris." Archives of Dermatology. 1989. doi:10.1001/archderm.1989.01670200119019
  38. Katsambas A, et al. "A Double-Blind Comparison of the Efficacy of Salicylic Acid vs Benzoyl Peroxide Acne Treatment Regimen for Acne Vulgaris." Journal of the American Academy of Dermatology. 2003. doi:10.1016/S0190-9622(03)03386-3
  39. Czernielewski J, et al. "Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations in Combating Rising Resistance in Cutibacterium acnes." Clinical, Cosmetic and Investigational Dermatology. 2025. doi:10.2147/CCID.S508977
MAXXING

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. All product claims use supports-language only. Benzoyl peroxide and other topical actives mentioned here should be patch-tested before use. Consult a licensed dermatologist if you have persistent, severe, or cystic acne, or if you experience significant adverse reactions to any topical treatment. MAXXING does not sell a benzoyl peroxide product; Clear Dominance is a niacinamide and zinc serum, not an acne medication.

© 2026 MAXXING LLC  |  trymaxxing.com  |  @trymaxxing

Back to blog